This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

AVROBIO (AVRO) Panoramica del titolo

A clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Maggiori dettagli

AVRO analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	0/6
Prestazioni passate	3/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Il rapporto prezzo/utile ( 24.9 x) è inferiore alla media del settore Biotechs ( 16.2 x)

È diventato redditizio quest'anno

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Si prevede che gli utili diminuiranno in media di 18.4% all'anno per i prossimi 3 anni

Grandi elementi una tantum che incidono sui risultati finanziari

Non ha una capitalizzazione di mercato significativa ( $64M )

AVRO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di AVROBIO, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per AVROBIO
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$16.80
Massimo di 52 settimane	US$19.80
Minimo di 52 settimane	US$10.56
Beta	1.22
Variazione di 1 mese	1.45%
Variazione a 3 mesi	9.38%
Variazione di 1 anno	44.82%
Variazione a 3 anni	-85.45%
Variazione a 5 anni	-90.89%
Variazione dall'IPO	-95.51%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Oct 18

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to Avrobio's (NASDAQ:AVRO) gene therapy AVR-RD-02 to treat Gaucher disease. The Innovation Passport is the first step in the ILAP process for regulatory and development milestones with the aim of early patient access in the U.K., the company said in a statement on Tuesday. Avrobio's noted that AVR-RD-02 has previously received fast track status in the U.S. and orphan drug designations in the U.S. and EU. Gaucher disease is a rare lysosomal disorder caused by buildup of certain fatty substances in organs, mainly the in the spleen and liver. AVRO +8.65% to $0.66 premarket Oct. 18

Seeking Alpha • Sep 20

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to Avrobio's (NASDAQ:AVRO) gene therapy AVR-RD-04 to treat cystinosis. Cystinosis is a rare, multisystem genetic disorder characterized by the excess build up of an amino acid called cystine in different tissues and organs, with the most affected being the kidneys, and eyes. This can damage the kidneys and can progress to end-stage kidney disease. AVR-RD-04 is designed to genetically modify patients' own hematopoietic stem cells (HSCs) to express the gene encoding cystinosin, the protein which is deficient in people living with cystinosis, the company said in a Sept. 20 press release. Avrobio added that AVR-RD-04 is the first gene therapy in development for cystinosis. AVRO +6.25% to $0.85 premarket Sept. 20

Seeking Alpha • Jul 13

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

The shares of gene therapy company AVROBIO (NASDAQ:AVRO) jumped ~9% in the pre-market Monday after the company announced that the FDA awarded the orphan drug designation for AVR-RD-05, a gene therapy candidate for mucopolysaccharidosis type II (MPSII), or Hunter syndrome. MPSII belong to a group of inherited metabolic disorders collectively called mucopolysaccharidosis. The rare lysosomal disorder primarily affects young boys. With its orphan drug designation, the FDA aims to offer financial incentives to drug developers targeting rare diseases and conditions. In addition to tax credits for clinical trial costs and waiver of the user fee for marketing applications, the developers of orphan drugs can claim seven years of marketing exclusivity upon regulatory approval of the treatment. In 2023, AVROBIO (AVRO) plans to start a Phase 1/2 clinical trial for Hunter syndrome in collaboration with the University of Manchester, UK.

Articolo di analisi • Nov 13

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Articolo di analisi • Aug 10

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Articolo di analisi • Mar 08

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Articolo di analisi • Nov 23

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Rendimenti per gli azionisti

	AVRO	US Biotechs	US Mercato
7D	-4.8%	2.4%	1.1%
1Y	44.8%	34.6%	28.7%

Ritorno vs Industria: AVRO ha superato il US Biotechs che ha restituito 34.6 % nell'ultimo anno.

Rendimento vs Mercato: AVRO ha superato il mercato US che ha restituito 28.7 % nell'ultimo anno.

Volatilità dei prezzi

Is AVRO's price volatile compared to industry and market?
AVRO volatility
AVRO Average Weekly Movement	5.6%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: AVRO non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di AVRO è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2015	13	Erik Ostrowski	www.avrobio.com

AVROBIO, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di AVROBIO con la sua capitalizzazione di mercato?
AVRO statistiche fondamentali
Capitalizzazione di mercato	US$63.75m
Utili (TTM)	US$30.31m
Ricavi(TTM)	n/a

24.9x

Rapporto P/E

0.0x

Rapporto P/S

AVRO è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
AVRO Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	-US$30.31m
Utili	US$30.31m

Ultimi utili riportati

Mar 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.68
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato AVRO nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/06/20 20:17
Prezzo dell'azione a fine giornata	2024/06/20 00:00
Utili	2024/03/31
Utili annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

AVROBIO, Inc. è coperta da 15 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Yun Zhong	Brean Capital Historical (Janney Montgomery)
Yun Zhong	BTIG
Whitney Ijem	Guggenheim Securities, LLC

This company is no longer active

AVROBIO (AVRO) Panoramica del titolo

Premi

Analisi del rischio

Concorrenti di AVROBIO, Inc.

Spero Therapeutics

Eagle Pharmaceuticals

Protalix BioTherapeutics

CytomX Therapeutics

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

Price target raised to US$38.50

Avrobio, Inc. Enters into Agreement with University of Manchester, England

Avrobio, Inc. Receives Orphan Drug Designation from the European Medicines Agency for Avr-Rd-02, an Investigational Gene Therapy for Gaucher Disease

New 90-day low: US$15.00

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

AVROBIO, Inc. Riepilogo dei fondamenti

Utili e ricavi